Business, Healthcare, Science

ENHERTU® approved in the US as first HER2 directed therapy for patients with HER2 low or HER2 ultralow metastatic breast cancer following disease progression after one or more endocrine therapies

Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings Daiichi Sankyo and AstraZeneca’s ENHERTU to an earlier HR positive treatment setting and broadens the patient

Business, Cultural Corner, Media & Communications, Travel & Venues

Sky Harbour Group to ring closing bell at the NYSE to mark uplisting and 3rd anniversary as a public company; announces investor conference schedule for first half of 2025

WEST HARRISON, N.Y. — (BUSINESS WIRE) — Sky Harbour Group Corporation (NYSE American: SKYH, SKYH WS) (“SHG” or the “Company”), an aviation infrastructure company building the first nationwide network of Home-Basing campuses for business aircraft, announced on Saturday that the Company will